The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

Charles Yates, Wenhui Zhang, Pengfei Song, Shen Li, A. Osama Gaber, Malak Kotb, Marsha R. Honaker, Rita R. Alloway, Bernd Meibohm

Research output: Contribution to journalArticle

154 Citations (Scopus)

Abstract

Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability. Racial differences in polymorphic expression of CYP3A5 und MDR1 may explain observed interracial variability in oral bioavailability. Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition. Steady-state plasma concentration profiles (n = 19) were sampled in renal transplant recipients receiving concentration-adjusted CsA maintenance therapy. CsA plasma concentrations were measured by fluorescence polarization immunoassay. CYP3A5 and MDR1 genotypes were determined by real-time polymerase chain reaction. Noncompartmental pharmacokinetic analysis and nonlinear mixed-effects modeling (NONMEM) were performed to assess the effect of genotype on CsA pharmacokinetics. MDR1 C3435T genotype was identified as the best predictor of CsA systemic exposure. CsA oral clearance was significantly higherin subjects who carried atleast one 3435T allele compared to homozygous wild-type individuals (40.0 ± 2.2 vs. 26.4 ± 3.1 L/h, p = 0.007). MDR1 C3435T genotype accounted for 43% of the interindividual variability of CsA oral clearance in the study population after accounting for interoccasion variability. The authors were unable to independently assess whether CYP3A5 correlated with any CsA pharmacokinetic parameter since all CYP3A5 nonexpressors were also 3435T allele carriers. MDR1 3435T allele carriers have enhanced oral clearance compared to individuals with the CC genotype. The frequency of the 3435T allele is lower in African Americans compared to Caucasians. Thus, the MDR1 C3435T genotype offers a potential mechanistic basis to explain interracial differences in CsA oral bioavailability. Further studies are needed to explore the relationship between CYP3A5 and MDR1 genotype and phenotype.

Original languageEnglish (US)
Pages (from-to)555-564
Number of pages10
JournalJournal of Clinical Pharmacology
Volume43
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

Cytochrome P-450 CYP3A
Cyclosporine
Transplants
Kidney
Genotype
Biological Availability
Pharmacokinetics
Alleles
Fluorescence Polarization Immunoassay
P-Glycoprotein
Gene Frequency
African Americans
Real-Time Polymerase Chain Reaction
Phenotype

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. / Yates, Charles; Zhang, Wenhui; Song, Pengfei; Li, Shen; Gaber, A. Osama; Kotb, Malak; Honaker, Marsha R.; Alloway, Rita R.; Meibohm, Bernd.

In: Journal of Clinical Pharmacology, Vol. 43, No. 6, 01.06.2003, p. 555-564.

Research output: Contribution to journalArticle

Yates, Charles ; Zhang, Wenhui ; Song, Pengfei ; Li, Shen ; Gaber, A. Osama ; Kotb, Malak ; Honaker, Marsha R. ; Alloway, Rita R. ; Meibohm, Bernd. / The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. In: Journal of Clinical Pharmacology. 2003 ; Vol. 43, No. 6. pp. 555-564.
@article{38ecd43857f04b4e9e12b1993a7e3f91,
title = "The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients",
abstract = "Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability. Racial differences in polymorphic expression of CYP3A5 und MDR1 may explain observed interracial variability in oral bioavailability. Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition. Steady-state plasma concentration profiles (n = 19) were sampled in renal transplant recipients receiving concentration-adjusted CsA maintenance therapy. CsA plasma concentrations were measured by fluorescence polarization immunoassay. CYP3A5 and MDR1 genotypes were determined by real-time polymerase chain reaction. Noncompartmental pharmacokinetic analysis and nonlinear mixed-effects modeling (NONMEM) were performed to assess the effect of genotype on CsA pharmacokinetics. MDR1 C3435T genotype was identified as the best predictor of CsA systemic exposure. CsA oral clearance was significantly higherin subjects who carried atleast one 3435T allele compared to homozygous wild-type individuals (40.0 ± 2.2 vs. 26.4 ± 3.1 L/h, p = 0.007). MDR1 C3435T genotype accounted for 43{\%} of the interindividual variability of CsA oral clearance in the study population after accounting for interoccasion variability. The authors were unable to independently assess whether CYP3A5 correlated with any CsA pharmacokinetic parameter since all CYP3A5 nonexpressors were also 3435T allele carriers. MDR1 3435T allele carriers have enhanced oral clearance compared to individuals with the CC genotype. The frequency of the 3435T allele is lower in African Americans compared to Caucasians. Thus, the MDR1 C3435T genotype offers a potential mechanistic basis to explain interracial differences in CsA oral bioavailability. Further studies are needed to explore the relationship between CYP3A5 and MDR1 genotype and phenotype.",
author = "Charles Yates and Wenhui Zhang and Pengfei Song and Shen Li and Gaber, {A. Osama} and Malak Kotb and Honaker, {Marsha R.} and Alloway, {Rita R.} and Bernd Meibohm",
year = "2003",
month = "6",
day = "1",
doi = "10.1177/0091270003253617",
language = "English (US)",
volume = "43",
pages = "555--564",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients

AU - Yates, Charles

AU - Zhang, Wenhui

AU - Song, Pengfei

AU - Li, Shen

AU - Gaber, A. Osama

AU - Kotb, Malak

AU - Honaker, Marsha R.

AU - Alloway, Rita R.

AU - Meibohm, Bernd

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability. Racial differences in polymorphic expression of CYP3A5 und MDR1 may explain observed interracial variability in oral bioavailability. Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition. Steady-state plasma concentration profiles (n = 19) were sampled in renal transplant recipients receiving concentration-adjusted CsA maintenance therapy. CsA plasma concentrations were measured by fluorescence polarization immunoassay. CYP3A5 and MDR1 genotypes were determined by real-time polymerase chain reaction. Noncompartmental pharmacokinetic analysis and nonlinear mixed-effects modeling (NONMEM) were performed to assess the effect of genotype on CsA pharmacokinetics. MDR1 C3435T genotype was identified as the best predictor of CsA systemic exposure. CsA oral clearance was significantly higherin subjects who carried atleast one 3435T allele compared to homozygous wild-type individuals (40.0 ± 2.2 vs. 26.4 ± 3.1 L/h, p = 0.007). MDR1 C3435T genotype accounted for 43% of the interindividual variability of CsA oral clearance in the study population after accounting for interoccasion variability. The authors were unable to independently assess whether CYP3A5 correlated with any CsA pharmacokinetic parameter since all CYP3A5 nonexpressors were also 3435T allele carriers. MDR1 3435T allele carriers have enhanced oral clearance compared to individuals with the CC genotype. The frequency of the 3435T allele is lower in African Americans compared to Caucasians. Thus, the MDR1 C3435T genotype offers a potential mechanistic basis to explain interracial differences in CsA oral bioavailability. Further studies are needed to explore the relationship between CYP3A5 and MDR1 genotype and phenotype.

AB - Variability in CYP3A (CYP3A4/5) and P-glycoprotein (human MDR1 gene product) activity underlies interindividual differences in oral cyclosporine (CsA) bioavailability. Racial differences in polymorphic expression of CYP3A5 und MDR1 may explain observed interracial variability in oral bioavailability. Our objective was to evaluate the effect of CYP3A5 and MDR1 polymorphic expression on CsA oral disposition. Steady-state plasma concentration profiles (n = 19) were sampled in renal transplant recipients receiving concentration-adjusted CsA maintenance therapy. CsA plasma concentrations were measured by fluorescence polarization immunoassay. CYP3A5 and MDR1 genotypes were determined by real-time polymerase chain reaction. Noncompartmental pharmacokinetic analysis and nonlinear mixed-effects modeling (NONMEM) were performed to assess the effect of genotype on CsA pharmacokinetics. MDR1 C3435T genotype was identified as the best predictor of CsA systemic exposure. CsA oral clearance was significantly higherin subjects who carried atleast one 3435T allele compared to homozygous wild-type individuals (40.0 ± 2.2 vs. 26.4 ± 3.1 L/h, p = 0.007). MDR1 C3435T genotype accounted for 43% of the interindividual variability of CsA oral clearance in the study population after accounting for interoccasion variability. The authors were unable to independently assess whether CYP3A5 correlated with any CsA pharmacokinetic parameter since all CYP3A5 nonexpressors were also 3435T allele carriers. MDR1 3435T allele carriers have enhanced oral clearance compared to individuals with the CC genotype. The frequency of the 3435T allele is lower in African Americans compared to Caucasians. Thus, the MDR1 C3435T genotype offers a potential mechanistic basis to explain interracial differences in CsA oral bioavailability. Further studies are needed to explore the relationship between CYP3A5 and MDR1 genotype and phenotype.

UR - http://www.scopus.com/inward/record.url?scp=0037906108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037906108&partnerID=8YFLogxK

U2 - 10.1177/0091270003253617

DO - 10.1177/0091270003253617

M3 - Article

VL - 43

SP - 555

EP - 564

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 6

ER -